Toggle Main Menu Toggle Search

Open Access padlockePrints

Systemic minocycline as a therapeutic option in predominantly oral mucous membrane pemphigoid: a cautionary report

Lookup NU author(s): Professor Marco Carrozzo

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

The aim of this study was to evaluate the therapeutic benefit of minocycline in mucous membrane pemphigoid (MMP) predominantly involving the oral cavity. A descriptive, open clinical study with no control group, including 9 patients, was developed. The diagnosis was confirmed by histopathological examination and direct and salt-split-skin indirect immunofluorescence analysis. Target antigens were sought by immunoblotting. Patients received minocycline (200 mg/day) for a variable period.. All patients were followed up for at least 2 years after initial diagnosis. Therapeutic response was assessed by clinical improvement in three categories: major response, minor response and no response. A major response was observed in 3 patients (33%), a minor response in 4 (44%) and 2 (22%) patients showed no improvement. Two of the 3 patients with a major response showed no immunoblot reactivity; 80% of patients with circulating autoantibodies (autoAb) against BP180 had a minor or no response. Permanent remission of signs with no relapse was only obtained in one patient. 5 patients (55%) stopped the drug because of adverse effects, such as vertigo and gastralgia. The results revealed temporary clinical benefits in MMP predominantly involving the oral cavity with minocycline, although frequently side effects led to drug withdrawal.


Publication metadata

Author(s): Carrozzo M, Arduino P, Bertolusso G, Cozzani E, Parodi A

Publication type: Article

Publication status: Published

Journal: International Journal of Oral and Maxillofacial Surgery

Year: 2009

Volume: 38

Issue: 10

Pages: 1071-1076

ISSN (print): 0901-5027

ISSN (electronic): 1399-0020

Publisher: Churchill Livingstone

URL: http://dx.doi.org/10.1016/j.ijom.2009.06.021

DOI: 10.1016/j.ijom.2009.06.021


Altmetrics

Altmetrics provided by Altmetric


Share